ACRS (Aclaris Therapeutics Inc.) Net Profit

ACRS (Aclaris Therapeutics, Inc.) - company brandmark

The daily price chart for Aclaris Therapeutics (ACRS) reflects the dynamics of a company implementing AI for rapid molecule selection in synthesis automation, although final tests require medical supervision. The business model is based on outsourcing early-stage research to external contractors, which mitigates production disruptions. The current metric stands at -0.08, confirming its status as a developer of innovative agents designed to strengthen the body's defensive functions.

ACRS (Aclaris Therapeutics) Net Profit history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company Aclaris Therapeutics, Inc. (ACRS)

- price and consensus price forecast:
Stock Quotes Aclaris Therapeutics, Inc|ACRS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Aclaris Therapeutics, Inc|ACRS - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Aclaris Therapeutics|ACRS - Book Capitalization|Market Capitalization to Book Value aclaristx.com|ACRS - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Aclaris Therapeutics|ACRS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Aclaris Therapeutics Inc.|ACRS - Company Total Debt|Debts to Book Capitalization Aclaris Therapeutics, Inc|ACRS - Company Long-Term Debt|Company Short-Term Indebtedness Aclaris Therapeutics|Immediate Liquidity aclaristx.com
- net income and valuation multiples indicators:
ACRS - Net Profit
Summary company analysis:Aclaris Therapeutics
Core merchandise of Aclaris

Institutional asset selection is based on the issuer's ability to maintain critical yield levels. This metric measures net income volatility and the deviation of operational efficiency from the norm. For Aclaris Therapeutics (ACRS), profit calculations depend directly on the success of clinical trials and the patent protection of molecules. GURU.Markets analytics allow for the assessment of impairment risk through the dynamics of the company's financial profit. The upward trend confirms the commercial viability of the biotechnological developments.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|PHAR - Net Profit|NKTR: Net Profit|Net Income upstreambio.com|Company Net Income Zenas Biopharma|Company Net Income IMNM|Net Profit GOSS|Net Profit KalVista Corp (KALV)|Company Net Income Septerna Inc SEPN|Final Profit PVLA|Savara - Net Profit|Net Financial Result Rigel Pharma RIGL|AnaptysBio Corp (ANAB) - Company Net Income|ATXS - Net Financial Result|Net Income ENGN|RAPT: Final Profit|Net Income JBIO (Aerovate Therapeutics Inc)|Profit After Payment of Taxes KYTX|Net Profit TLSA (Tiziana Life Sciences PLC)|Final Profit CABA|Ventyx Biosciences - Net Profit|Company Net Income theratech.com|Avalo Therapeutics (AVTX) - Company Net Income|Eledon Pharmaceuticals Inc. - Final Profit|AGEN (Agenus Inc) - Net Profit|Net Profit Climb Bio, Inc|Company Net Income Zura Bio Limited (ZURA)|ATYR: Profit After Tax|Net Profit ADAG (Adagene Inc.)|ImageneBio (IMA) - Company Net Income|STTK: Net Income|EQ - Net Profit|CNTB (connectbiopharm.com) - Net Income|IMUX: Profit After Payment of Taxes|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|InflaRx GmbH (IFRX) - Net Financial Result|Net Profit XFOR|Net Income adicetbio.com ACET|Company Net Income Celularity CELU|Net Financial Result inmunebio.com (INMB)|Barinthus Biotherapeutics plc - Net Profit|KZR - Net Profit|SABS: Net Profit|Net Income Akari Therapeutics, Plc|Company Net Income Enlivex Therapeutics Ltd|QTTB: Final Profit|Company Net Income GeoVax (GOVX)|Net Financial Result Edesa Biotech Inc|Company Net Income iBio Corp IBIO|CARM (Carisma Therapeutics Inc) - Profit After Tax|XTL Biopharmaceuticals - Net Profit|Final Profit BOLT (Bolt Biotherapeutics)|HCWB: Net Profit|Aptevo Therapeutics Inc. (APVO) - Net Profit|Company Net Income AIM ImmunoTech|ADTX: Final Profit|Company Net Income GRI Bio, Inc. (GRI)|Net Income xortx.com XRTX|Net Profit HIND (Vyome Holdings)|Net Profit Revelation Biosciences Inc REVB|INDP: Net Income|Final Profit SCNI (BiondVax Pharmaceuticals)|CALI: Net Profit|AFMD - Net Financial Result|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Company Net Income IGM Biosciences, Inc. (IGMS)|Net Income iTeos Pharma ITOS|Ocean Biomedical, Inc. - Net Income|Net Profit tcbiopharm.com TCBP|THRD - Company Net Income